In order to supervise the optimization of the medical infrastructure to conduct clinical trials of the COVID-19 vaccine, a group of researchers from Chinese laboratory Sinopharm
visited the facilities of San Marcos University's Clinical Trials Unit, the academic institution reported.
Thus, the Asian researchers finalize details to conduct Phase 3 clinical trials so as to evaluate the safety and protective efficacy of the inactivated vaccine against SARS-CoV-2 developed by the abovementioned pharmaceutical company.
This important research will involve 6,000 volunteers in total, who are required to evaluate the efficacy of the COVID-19 vaccine.
In the case of San Marcos, the clinical trials will be conducted by its Medical School, through the research group called "Clinical Research Unit of the Infectious and Tropical Diseases Service," led by Eduardo Ticona, infectious medicine doctor and senior lecturer at San Marcos University.
The academic institution reported that all the information on the vaccination and registration process of the 3,000 remaining volunteers will be available here